Viracta Therapeutics, Inc. financial data

Symbol
VIRX
Location
Cardiff, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 13 Nov 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 118% % -73%
Debt-to-equity 494% %
Return On Equity -680% % -554%
Return On Assets -114% % -95%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39,744,222 shares 2.9%
Common Stock, Shares, Outstanding 39,744,222 shares 2.9%
Common Stock, Value, Issued $4,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 39,574,070 shares 2.3%
Weighted Average Number of Shares Outstanding, Diluted 39,574,070 shares 2.3%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $14,119,000 USD -22%
Operating Income (Loss) $47,211,000 USD 3.1%
Net Income (Loss) Attributable to Parent $43,289,000 USD 9.1%
Earnings Per Share, Basic -1 USD/shares 11%
Earnings Per Share, Diluted -1 USD/shares 39%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $13,127,000 USD 2.1%
Cash, Cash Equivalents, and Short-term Investments $21,100,000 USD -67%
Assets, Current $21,803,000 USD -66%
Property, Plant and Equipment, Net $111,000 USD -49%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $44,000 USD -97%
Assets $21,958,000 USD -67%
Accounts Payable, Current $1,817,000 USD -23%
Employee-related Liabilities, Current $739,000 USD -68%
Accrued Liabilities, Current $9,847,000 USD 16%
Liabilities, Current $28,575,000 USD -22%
Liabilities $28,575,000 USD -22%
Accumulated Other Comprehensive Income (Loss), Net of Tax $9,000 USD
Retained Earnings (Accumulated Deficit) $295,456,000 USD -17%
Stockholders' Equity Attributable to Parent $6,617,000 USD -122%
Liabilities and Equity $21,958,000 USD -67%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,849,000 USD 31%
Net Cash Provided by (Used in) Financing Activities $6,598,000 USD -141%
Net Cash Provided by (Used in) Investing Activities $14,192,000 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 39,744,222 shares 2.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13,127,000 USD 2.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities $851,000 USD 47%
Operating Lease, Liability $73,000 USD -85%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $43,215,000 USD 9%
Lessee, Operating Lease, Liability, to be Paid $73,000 USD -86%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $0 USD -100%
Preferred Stock, Shares Issued 0 shares -100%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $288,826,000 USD 4.4%
Preferred Stock, Shares Outstanding 0 shares -100%
Depreciation, Depletion and Amortization $110,000 USD -9.8%
Share-based Payment Arrangement, Expense $6,248,000 USD -22%
Interest Expense $3,184,000 USD 8.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%